Madrigal Pharmaceuticals, Inc. - Common Stock (NQ:MDGL)

509.99 -8.77 (-1.69%)

Streaming Delayed Price Updated: 1:58 PM EDT, Mar 27, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Madrigal Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Where Is The Current Bull Market? Scan Of Stocks Gaining Over 20% Over The Past Week Almost Exclusively Yields Biotech Names ↗

April 20, 2023

Where is the current bull market? All indications would be that it's in biotech! The broader market is not really moving. There have been plenty of attention-grabbing headlines, and earnings season is...

Via Benzinga

Why Top 1% Biotech Madrigal Pharmaceuticals Just Surged Closer To A Breakout ↗

April 18, 2023

Shares are closing in on a buy point after retaking their 50-day moving average.

Via Investor's Business Daily

Madrigal Pharmaceuticals Inc. (NASDAQ: MDGL) Making Surprising Moves in Tuesday Session

April 18, 2023

Via Investor Brand Network

5 Best Stocks to Buy in April ↗

April 01, 2023

These powerful trends should yield stellar returns for investors in April and beyond.

Via The Motley Fool

Up 463%, This Sizzling Growth Stock Could Have a Lot More Room to Run ↗

March 29, 2023

Viking Therapeutics stock might in the midst of a historic run.

Via The Motley Fool

Madrigal Pharmaceuticals Inc. (NASDAQ: MDGL) is a Leading Gainer in 3/17 Morning Trading

March 17, 2023

Via Investor Brand Network

2 Surging Healthcare Stocks That Are Still Worth Buying ↗

February 23, 2023

These two NASH drugmakers have a lot of room to run.

Via The Motley Fool

Here's How Much You Would Have Made Owning Madrigal Pharmaceuticals Stock In The Last 5 Years ↗

January 09, 2023

Via Benzinga

Is Viking Therapeutics a Smart Buy on the Dip? ↗

March 27, 2023

The stock recently fell around 25% for reasons that had nothing to do with its lead program.

Via The Motley Fool

Want Diversified Upside in Biotechnology? Check out LABU

March 22, 2023

Watch the Direxion Daily S&P 500 Biotech Bull 3X Shares (NYSEARCA: LABU) if you want a speculative play in the biotechnology industry with amplified volatility.

Via MarketBeat

Topics ETFs Stocks

The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector ↗

March 15, 2023

To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy.

Via InvestorPlace

Intercept Tumbles As Its Experimental NASH Drug Faces Yet Another Obstacle ↗

March 10, 2023

Meanwhile, the company is facing a stout rival in the form of Madrigal Pharmaceuticals.

Via Investor's Business Daily

If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,800 Today ↗

December 23, 2022

Via Benzinga

1 Incredible Growth Stock That Could Turn $200,000 Into $1 Million by 2030 ↗

March 09, 2023

This clinical-stage biopharma stock could harbor one of the best-selling drugs of all time.

Via The Motley Fool

3 Incredible Growth Stocks to Buy if the Market Dips ↗

March 02, 2023

These top growth stocks sport premium valuations for a very good reason.

Via The Motley Fool

3 Top Healthcare Stocks to Buy for January ↗

January 11, 2023

These healthcare stocks have a lot going for them in the new year.

Via The Motley Fool

CRISPR, Genetics And AI — Why 2023 Could Be The Year For Biotech Stocks ↗

January 06, 2023

Genetic medicine is a top theme now for biotech stocks. Other trends are heating up too.

Via Investor's Business Daily

5 Most Expensive Health Care Stocks You Should Worry About ↗

January 03, 2023

The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.

Via Benzinga

Why These 7 Healthcare Stocks Could Soar in 2023 ↗

January 02, 2023

These healthcare stocks to buy are trading at a hefty discount and are poised to deliver robust returns in 2023.

Via InvestorPlace

5 Top Stocks for January ↗

January 01, 2023

Now is the time to begin crafting your watch list for 2023.

Via The Motley Fool

Singing Machine, Blue Apron, Camber Energy And More Short Squeeze Candidates That Could Soar This Week ↗

December 27, 2022

Potential short squeeze plays gained steam in 2021 and have continued through 2022, with new traders looking for the next huge move. High short interest and a high cost to borrow are among the common...

Via Benzinga

This Stock That Tripled in 2022 Could Rocket Even Higher in 2023 ↗

December 26, 2022

Potential suitors with heaps of cash to spend are lining up to get a closer look at this company's results.

Via The Motley Fool

Stock Market Falls Sharply Again As Tesla Dives, Micron Hits Chips; Nike, FedEx Strong: Weekly Review ↗

December 23, 2022

The market uptrend is under pressure.

Via Investor's Business Daily

Universal Health Services, Madrigal Pharmaceuticals And These Overbought Majors In The Healthcare Sector ↗

December 23, 2022

The most overbought stocks in the healthcare sector presents an opportunity to go short on these overvalued companies.

Via Benzinga

Why Madrigal Pharmaceuticals Was a Top Stock This Week ↗

December 23, 2022

Biotech bulls stampeded the company following its latest clinical update.

Via The Motley Fool

7 Drug Stocks That Will Soar in 2023 ↗

December 22, 2022

These drug stocks to buy look poised to generate huge profits for investors in 2023 and in subsequent years.

Via InvestorPlace

Earnings Optimism Puts Wind In Wall Street's Sails ↗

December 21, 2022

The major indexes are extending their rally off a mid-December losing streak.

Via Talk Markets

Why Did Viking Therapeutics Stock Skyrocket

December 21, 2022

VKTX stock is young but strong and they have excellent potential, particularly following successful trial results from Madrigal Pharma's recent drug trial.

Via MarketBeat

Top M&A Target: Madrigal Pharmaceuticals Could Be Next After Successful NASH Data, Analyst Says ↗

December 20, 2022

Via Benzinga

Madrigal Pharmaceuticals Gets Price Target Bumps By Analysts Following Successful NASH Study ↗

December 20, 2022

Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) announced positive topline results from the pivotal Phase 3 MAESTRO-NASH biopsy trial of resmetirom. Madrigal Pharmaceuticals shares jumped 268.1% to close...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.